Target Corporation (TGT)
Live price chart, market sentiment, and community perspectives for Target Corporation (NYSE: TGT).
Live price chart, market sentiment, and community perspectives for Target Corporation (NYSE: TGT).
On our desk, TGT's recent price action has been fascinating to dissect. Trading at around $151.01 with a 1-year return topping 43%, the stock is displaying strong upward momentum. However, looking at the consensus analyst price targets clustering tightly around $143.87 to $144.40, we see clear hesitation from major firms like Baird, Piper Sandler, and Truist, all maintaining Hold ratings with slight downside percentages. While the Q2 2026 earnings beat by 15.8% gave bulls something to cheer about, the RSI sitting near 73.92 suggests we might be entering overbought territory as it approaches the $156.50 resistance ceiling.
When evaluating retail sector execution protocols with our research teams, TGT's balance sheet structure deserves meticulous scrutiny. SEC filings show $8.3 billion remaining in authorized share repurchase capacity as of early 2026, alongside a book value per share of $36.10 and a market capitalization hovering near $68.59 billion. When grilling candidates on valuation methodologies during our internal case reviews, analysts must reconcile how a stock with a 10.29 EV/EBITDA multiple and a 1.01 beta can trade past consensus targets while maintaining heavy retail and institutional chatter across forums regarding its structural volatility.
As a quant reviewing the fundamental scorecard, Target's valuation parameters present a distinct profile. The trailing P/E stands at 20.02 with a robust gross profit margin of 28.1% and a return on equity hitting 22%. What stands out most for long-term income allocation is the unmatched consistency of its dividend track record—having raised payouts for 55 consecutive years, accompanied by upcoming dividend dates in mid-2026. Nevertheless, with 15 analysts revising earnings upwards for the upcoming period, execution risk remains high heading into the August 19, 2026 earnings release, particularly given that current prices sit above several institutional consensus targets.
Explore plasma cleansing, somatic organ swaps, and BCI.